Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$103.95 USD
-0.28 (-0.27%)
Updated May 24, 2024 04:00 PM ET
After-Market: $103.94 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$103.95 USD
-0.28 (-0.27%)
Updated May 24, 2024 04:00 PM ET
After-Market: $103.94 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Abiomed's Latest Regulatory Progress Boosts Impella Line
by Zacks Equity Research
We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.
Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.
4 Top MedTech Stocks for Dividend Investors in 2017
by Zacks Equity Research
Dividend stocks are always investors' preferred choice as they provide steady income and cushion against market risks.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.
Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead
by Zacks Equity Research
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.
Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm
by Zacks Equity Research
Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.
Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
by Zacks Equity Research
Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.
Agilent (A) Sues Former Employees for Infringing IP Rights
by Zacks Equity Research
Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.
Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?
by Zacks Equity Research
Abbott Laboratories (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott-North West London Pathology Expand in Diagnostics
by Zacks Equity Research
Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
Profit from the Dollar's Dip with These 5 S&P 500 Stocks
by Swarup Gupta
Companies with significant overseas exposure stand to gain from the dollar's dip.
Company News for July 21, 2017
by Zacks Equity Research
Companies In The News are: ABT,KMI,PM,TRV
Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up
by Zacks Equity Research
Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.
Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales
by Zacks Equity Research
Abbott Laboratories (ABT) gains on strong Q2 performance. Raised guidance buoys optimism.
The Hottest Earnings Charts of the Week
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing it.
Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More
by Zacks Equity Research
The market remained jittery towards medical space due to uncertainties surrounding the future of the healthcare act.
Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.
Abbott Partners Bigfoot Biomedical to Expand in Diabetics
by Zacks Equity Research
Illinois-based global medical device company Abbott Laboratories (ABT) partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.
Edwards Emerges Strong on FDA Nods, International Prospect
by Zacks Equity Research
On Jul 11, we issued an updated research report on the leading molecular diagnostic company, Edwards Lifesciences Corporation (EW).
LabCorp Diagnostics Strong on Novant Health Deal Extension
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH), also referred to as LabCorp, has decided to extend its Technical Services Agreement with Novant Health which was originated in 2012.
Medtronic (MDT) Launches Resolute Onyx DES Device in Japan
by Zacks Equity Research
Medtronic plc (MDT), a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest revenue grossing Cardiovascular segment.
Thermo Fisher at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Thermo Fisher Scientific Inc. (TMO), headquartered in Waltham, MA, scaled a new 52-week high of $177.99 on Jul 7, eventually closing a shade lower at $177.49.